請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/59402
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 黃銓珍(Chang-Jen Huang) | |
dc.contributor.author | Ying-Yueh (Betty) Lee | en |
dc.contributor.author | 李盈玥 | zh_TW |
dc.date.accessioned | 2021-06-16T09:22:40Z | - |
dc.date.available | 2020-08-25 | |
dc.date.copyright | 2017-08-25 | |
dc.date.issued | 2017 | |
dc.date.submitted | 2017-06-24 | |
dc.identifier.citation | Ballantyne, A. D., and K. P. Garnock-Jones. 2013. 'Dabrafenib: first global approval', Drugs, 73: 1367-76.
Cardamone, M., B. T. Darras, and M. M. Ryan. 2008. 'Inherited myopathies and muscular dystrophies', Semin Neurol, 28: 250-9. Chawla, J. 2011. 'Stepwise approach to myopathy in systemic disease', Front Neurol, 2: 49. Christofferson, D. E., and J. Yuan. 2010. 'Necroptosis as an alternative form of programmed cell death', Curr Opin Cell Biol, 22: 263-8. Dalakas, M. C. 2011. 'Pathophysiology of inflammatory and autoimmune myopathies', Presse Med, 40: e237-47. Degterev, A., J. Hitomi, M. Germscheid, I. L. Ch'en, O. Korkina, X. Teng, D. Abbott, G. D. Cuny, C. Yuan, G. Wagner, S. M. Hedrick, S. A. Gerber, A. Lugovskoy, and J. Yuan. 2008. 'Identification of RIP1 kinase as a specific cellular target of necrostatins', Nat Chem Biol, 4: 313-21. Galluzzi, L., and G. Kroemer. 2008. 'Necroptosis: a specialized pathway of programmed necrosis', Cell, 135: 1161-3. Geserick, P., J. Wang, R. Schilling, S. Horn, P. A. Harris, J. Bertin, P. J. Gough, M. Feoktistova, and M. Leverkus. 2015. 'Absence of RIPK3 predicts necroptosis resistance in malignant melanoma', Cell Death Dis, 6: e1884. Glaze, E. R., A. L. Lambert, A. C. Smith, J. G. Page, W. D. Johnson, D. L. McCormick, A. P. Brown, B. S. Levine, J. M. Covey, M. J. Egorin, J. L. Eiseman, J. L. Holleran, E. A. Sausville, and J. E. Tomaszewski. 2005. 'Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance', Cancer Chemother Pharmacol, 56: 637-47. Hatcher, H., R. Planalp, J. Cho, F. M. Torti, and S. V. Torti. 2008. 'Curcumin: from ancient medicine to current clinical trials', Cell Mol Life Sci, 65: 1631-52. Hauschild, A., J. J. Grob, L. V. Demidov, T. Jouary, R. Gutzmer, M. Millward, P. Rutkowski, C. U. Blank, W. H. Miller, Jr., E. Kaempgen, S. Martin-Algarra, B. Karaszewska, C. Mauch, V. Chiarion-Sileni, A. M. Martin, S. Swann, P. Haney, B. Mirakhur, M. E. Guckert, V. Goodman, and P. B. Chapman. 2012. 'Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial', Lancet, 380: 358-65. Kamal, A., M. F. Boehm, and F. J. Burrows. 2004. 'Therapeutic and diagnostic implications of Hsp90 activation', Trends Mol Med, 10: 283-90. Lalaoui, N., and G. Brumatti. 2017. 'Relevance of necroptosis in cancer', Immunol Cell Biol, 95: 137-45. Li, J. X., J. M. Feng, Y. Wang, X. H. Li, X. X. Chen, Y. Su, Y. Y. Shen, Y. Chen, B. Xiong, C. H. Yang, J. Ding, and Z. H. Miao. 2014. 'The B-Raf(V600E) inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury', Cell Death Dis, 5: e1278. Linkermann, A., and D. R. Green. 2014. 'Necroptosis', N Engl J Med, 370: 455-65. Liu, Y. C., and A. S. Chiang. 2003. 'High-resolution confocal imaging and three-dimensional rendering', Methods, 30: 86-93. Madrigal-Matute, J., C. E. Fernandez-Garcia, C. Gomez-Guerrero, O. Lopez-Franco, B. Munoz-Garcia, J. Egido, L. M. Blanco-Colio, and J. L. Martin-Ventura. 2012. 'HSP90 inhibition by 17-DMAG attenuates oxidative stress in experimental atherosclerosis', Cardiovasc Res, 95: 116-23. Negroni, A., S. Cucchiara, and L. Stronati. 2015. 'Apoptosis, Necrosis, and Necroptosis in the Gut and Intestinal Homeostasis', Mediators Inflamm, 2015: 250762. Orrell, R. W. 2007. 'Endocrine myopathies', Handb Clin Neurol, 86: 343-55. Panda, A. K., D. Chakraborty, I. Sarkar, T. Khan, and G. Sa. 2017. 'New insights into therapeutic activity and anticancer properties of curcumin', J Exp Pharmacol, 9: 31-45. Park, S. Y., J. H. Shim, J. I. Chae, and Y. S. Cho. 2015. 'Heat shock protein 90 inhibitor regulates necroptotic cell death via down-regulation of receptor interacting proteins', Pharmazie, 70: 193-8. Pasnoor, M., R. J. Barohn, and M. M. Dimachkie. 2014. 'Toxic myopathies', Neurol Clin, 32: 647-70, viii. Pasparakis, M., and P. Vandenabeele. 2015. 'Necroptosis and its role in inflammation', Nature, 517: 311-20. Rheault, T. R., J. C. Stellwagen, G. M. Adjabeng, K. R. Hornberger, K. G. Petrov, A. G. Waterson, S. H. Dickerson, R. A. Mook, Jr., S. G. Laquerre, A. J. King, O. W. Rossanese, M. R. Arnone, K. N. Smitheman, L. S. Kane-Carson, C. Han, G. S. Moorthy, K. G. Moss, and D. E. Uehling. 2013. 'Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors', ACS Med Chem Lett, 4: 358-62. Sun, X., J. A. Bristol, S. Iwahori, S. R. Hagemeier, Q. Meng, E. A. Barlow, J. D. Fingeroth, V. L. Tarakanova, R. F. Kalejta, and S. C. Kenney. 2013. 'Hsp90 inhibitor 17-DMAG decreases expression of conserved herpesvirus protein kinases and reduces virus production in Epstein-Barr virus-infected cells', J Virol, 87: 10126-38. Takahashi, N., L. Duprez, S. Grootjans, A. Cauwels, W. Nerinckx, J. B. DuHadaway, V. Goossens, R. Roelandt, F. Van Hauwermeiren, C. Libert, W. Declercq, N. Callewaert, G. C. Prendergast, A. Degterev, J. Yuan, and P. Vandenabeele. 2012. 'Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models', Cell Death Dis, 3: e437. Taldone, T., A. Gozman, R. Maharaj, and G. Chiosis. 2008. 'Targeting Hsp90: small-molecule inhibitors and their clinical development', Curr Opin Pharmacol, 8: 370-4. Vanden Berghe, T., N. Vanlangenakker, E. Parthoens, W. Deckers, M. Devos, N. Festjens, C. J. Guerin, U. T. Brunk, W. Declercq, and P. Vandenabeele. 2010. 'Necroptosis, necrosis and secondary necrosis converge on similar cellular disintegration features', Cell Death Differ, 17: 922-30. Vandenabeele, P., S. Grootjans, N. Callewaert, and N. Takahashi. 2013. 'Necrostatin-1 blocks both RIPK1 and IDO: consequences for the study of cell death in experimental disease models', Cell Death Differ, 20: 185-7. Wang, Y. L., H. H. Shen, P. Y. Cheng, Y. J. Chu, H. R. Hwang, K. K. Lam, and Y. M. Lee. 2016. '17-DMAG, an HSP90 Inhibitor, Ameliorates Multiple Organ Dysfunction Syndrome via Induction of HSP70 in Endotoxemic Rats', PLoS One, 11: e0155583. Wu, W., P. Liu, and J. Li. 2012. 'Necroptosis: an emerging form of programmed cell death', Crit Rev Oncol Hematol, 82: 249-58. Xie, T., W. Peng, Y. Liu, C. Yan, J. Maki, A. Degterev, J. Yuan, and Y. Shi. 2013. 'Structural basis of RIP1 inhibition by necrostatins', Structure, 21: 493-9. Yang, C. K., and S. D. He. 2016. 'Heat shock protein 90 regulates necroptosis by modulating multiple signaling effectors', Cell Death Dis, 7: e2126. Zhao, H., T. Jaffer, S. Eguchi, Z. Wang, A. Linkermann, and D. Ma. 2015. 'Role of necroptosis in the pathogenesis of solid organ injury', Cell Death Dis, 6: e1975. Zhou, H., C. S. Beevers, and S. Huang. 2011. 'The targets of curcumin', Curr Drug Targets, 12: 332-47. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/59402 | - |
dc.description.abstract | 細胞壞死性凋亡(Necroptosis)是一種利用絲/蘇安酸激酶和受體 (receptor-interacting serine/threonine protein kinases; RIPK)交互作用的非依賴凋亡蛋白酶(caspase)式的調節性細胞死亡。先前研究指出其功能廣泛參與於發炎反應、自體免疫、以及神經退化性疾病等。此外 heat shock protein 90 (hsp90) 蛋白曾被報導在細胞壞死性凋亡中具有重要角色,包含可以穩定RIP1蛋白(receptor-interacting protein 1)的穩定性以及RIP3蛋白(receptor-interacting protein 3)的啟動等。實驗室先前的研究證明了細胞凋亡以及細胞壞死性凋亡皆會參與薑黃素(curcumin)引發斑馬魚的肌肉病變以及尾部潰爛的現象中。將受精後24小時的斑馬魚胚胎浸泡在具有薑黃素的養殖水中再依序加入necrostatin-1 (RIP1 抑制劑)、dabrafenib (RIP3 抑制劑、17-DMAG (hsp90 抑制劑) 處理三小時後,發現薑黃素引發斑馬魚的尾部潰爛的現象中可能為 rip-1、rip3依賴性的途徑,且可被其抑制劑阻斷潰爛現象發生。在此實驗中,我們透過TUNEL assay 以及切割的 caspase-3 抗體免疫染色以及西方墨點法實驗進一步確認細胞凋亡途徑參與在薑黃素引發斑馬魚的尾部潰爛現象中。我們也同時偵測了斑馬魚胚胎中RIP1的蛋白表現量在此過程中的變化以及其角色。接著我們使用不同濃度的17-DMAG 去抑制薑黃素引發斑馬魚的尾部潰爛的現象,並發現其為最有效率的抑制劑。綜合以上,我們的研究模式顯示hsp90在細胞壞死性凋亡的重要性以及證明了在薑黃素引發斑馬魚的尾部潰爛與細胞壞死性凋亡有重要的關聯性。 | zh_TW |
dc.description.abstract | Necroptosis is a caspase-independent form of regulated cell death that has been depended on the activity of receptor-interacting serine/threonine protein kinases. It has been implicated in the development of a range of inflammatory, autoimmune and neurodegenerative diseases. In addition, heat shock protein 90 (hsp90) has been reported to play important roles in necroptosis, including RIP1 (receptor-interacting protein 1) stability and RIP3 (receptor-interacting protein 3) activation. Previous studies indicated that both apoptosis and necroptosis were involved in the process of curcumin-induced myopathy in zebrafish. 24 hpf zebrafish embryos were treated with curcumin and followed by various known necroptosis inhibitors (necrostatin-1, dabrafenib, 17-DMAG) for 3 hr. The data suggested that curcumin-induced myopathy might be a rip1- and rip3-dependent pathway because of its inhibition by necroptosis inhibitors. In this study, we have further confirmed that apoptosis indeed plays a role in the progress of curcumin-induced myopathy in zebrafish by performing TUNEL assay and cleaved Caspase-3 to label cells that undergoing apoptosis. We also monitored the changes in rip1 protein expression in order to study the role of necroptosis in the progress of curcumin-induced myopathy in zebrafish. Next, we investigated the effect of 17-DMAG (hsp90 inhibitor) in curcumin-induced myopathy and were able to prove that 17-DMAG is the most powerful inhibitor to block the curcumin-induced myopathy progression in zebrafish. In summary, our model has revealed the importance of hsp90 in necroptosis pathway and the relationship between curcumin-induced myopathy and necroptosis. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T09:22:40Z (GMT). No. of bitstreams: 1 ntu-106-R04b46026-1.pdf: 15448482 bytes, checksum: 6236511ce8bc2bdc761b08e5a1b26b97 (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | 口試委員會審定書..................................................................................................i
Acknowledgement..............................................................................................ii 中文摘要.............................................................................................................iii Abstract.............................................................................................................iv Contents.............................................................................................................v Chapter 1 Introduction.......................................................................................1 1.1 Curcumin...................................................................................................1 1.2 Myopathy...................................................................................................1 1.3 Necroptosis................................................................................................2 1.4 Necrostatin-1.............................................................................................4 1.5 Dabrafenib.................................................................................................5 1.6 17-DMAG...................................................................................................6 1.7 Curcumin-Induced Myopathy......................................................................7 Chapter 2 Specific Aims......................................................................................9 Chapter 3 Materials and Methods......................................................................10 3.1 Zebrafish Care..........................................................................................10 3.2 Drug Treatment: Curcumin, Nec-1, Dabrafenib, NSA, 17-DMAG...............10 3.3 Whole-mount Immunostaining.................................................................10 3.4 TUNEL Assay.............................................................................................11 3.5 High-Resolution Confocal Imaging...........................................................11 3.6 Western Blot.............................................................................................12 Chapter 4 Results.............................................................................................13 4.1 Involvement of apoptosis in curcumin-induced myopathy in zebrafish......13 4.2 Elevation of rip1 protein level in curcumin-induced myopathy in zebrafish…………………………………………………………………........................…14 4.3 Curcumin-induced myopathy in zebrafish can be efficiently block by 17 DMAG...............................................................................................................15 Chapter 5 Discussion........................................................................................16 REFERENCE.......................................................................................................18 Figures.............................................................................................................21 APPENDIX.........................................................................................................28 | |
dc.language.iso | en | |
dc.title | 建立薑黃素引發斑馬魚肌肉之病變模式 | zh_TW |
dc.title | Establishment of a curcumin-induced myopathy in zebrafish | en |
dc.type | Thesis | |
dc.date.schoolyear | 105-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 張茂山(Mau-Sun Chang),鄭嘉雄(Chia-Hsiung Cheng) | |
dc.subject.keyword | 薑黃素,肌肉病變,細胞壞死性凋亡,necrostatin-1 (RIP1 抑制劑),dabrafenib (RIP3 抑制劑),17-DMAG (hsp90 抑制劑), | zh_TW |
dc.subject.keyword | curcumin,myopathy,necroptosis,necrostatin-1 (rip1 inhibitor),dabrafenib (rip3 inhibitor),17-DMAG (hsp90 inhibitor), | en |
dc.relation.page | 37 | |
dc.identifier.doi | 10.6342/NTU201701088 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2017-06-26 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生化科學研究所 | zh_TW |
顯示於系所單位: | 生化科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf 目前未授權公開取用 | 15.09 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。